Skip to content

CENTESSA PHARMACEUTICALS PLC

CNTA

CIK 0001847903

← back to feed
Revenue (TTM)
$15M
Q1 Apr 2026
Net Income (TTM)
−$210.61M
+16.2% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.51
+29.1% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-1,460.0%
Q1 Apr 2026
Net Margin
-1,404.1%
Q1 Apr 2026
Free Cash Flow (TTM)
−$214.97M
Q1 Apr 2026
Cash
$62.43M
Q1 Apr 2026
Total Debt
$116.07M
Q1 Apr 2026
Shares Outstanding
154.73M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings